法国赛诺菲的喜保宁在国内有吗？

Epilepsy, commonly known as "epilepsy" or "epilepsy", is a chronic disease in which brain nerves suddenly discharge abnormally, causing temporary brain dysfunction. According to China's latest epidemiological data, the overall prevalence of epilepsy in China is 7.0‰, the annual incidence rate is 28.8/100,000, and the prevalence of active epilepsy with seizures within 1 year is 4.6‰. A large part of the drugs currently used to treat epilepsy clinically achieve anti-epileptic pharmacological activity by inhibiting γ-aminobutyric acid aminotransferase, which is developed based on γ-aminobutyric acid aminotransferase and is currently an effective drug for the treatment of epilepsy. Sanofi (NYSE: SNY) was founded in 1973. Its predecessor was Sanofi-Aventis. It was changed to its current name: Sanofi in May 2011. It is headquartered in Paris, France, and has 113,496 full-time employees in more than 100 countries around the world. It is the world's leading diversified pharmaceutical and health company with diversified products, including drugs, vaccines and innovative treatment solutions.

Vigabatrin is an analog of γ-aminobutyric acid (GABA), which can specifically bind to GABA aminotransferase and irreversibly, leading to an increase in GABA concentration in the brain, thereby exerting anti-epileptic effects. Vigabatrin is used as adjunctive therapy in patients who are refractory to other antiepileptic drugs, especially those with partial seizures (mainly used to control complex partial seizures). Vigabatrin may worsen absence seizures or myoclonic seizures. Vigabatrin may also be used in infants with West syndrome (infantile spasms), which is generally unresponsive to conventional antiepileptic drugs. As an auxiliary treatment drug, Vigabatrin can achieve better efficacy. When used alone, it is effective in the treatment of newly diagnosed patients. The only fly in the ointment is that France's Sanofi's drug has not been launched in China, and patients in need of the drug can obtain it through domestic professional overseas medical service institutions.

Recommended related hot articles: /newsDetail/97423.html

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.